T1	Participants 68 102	patients with early breast cancer:
T2	Participants 345 460	285 premenopausal breast cancer patients, in a randomized adjuvant trial (Zoladex in premenopausal patients (ZIPP))
T3	Participants 508 530	Node positive patients
